Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free
Close

Sorrento Therape (SRNE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sorrento Therape's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.570 -0.010    -0.63%
30/09 - Closed. Currency in USD ( Disclaimer )
After Hours
1.610
+0.040
+2.548%
19:51:06 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 3,326,155
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.540 - 1.660
Sorrento Therape 1.570 -0.010 -0.63%

SRNE Financial Summary

 
A brief financial summary of Sorrento Therape as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Sorrento Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 11.46 million compared to USD 13.51 million a year ago. Net loss was USD 218.76 million compared to USD 166.62 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.57 a year ago. Diluted loss per share from continuing operations was USD 0.54 compared to USD 0.57 a year ago.For the six months, revenue was USD 29.85 million compared to USD 27.77 million a year ago. Net loss was USD 259.57 million compared to USD 164.11 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.58 a year ago. Diluted loss per share from continuing operations was USD 0.7 compared to USD 0.58 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SRNE Income Statement

Gross margin TTM -334.25%
Operating margin TTM -697.97%
Net Profit margin TTM -952.65%
Return on Investment TTM -94.46%
 Total Revenue  Net Income
Period Ending: Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Total Revenue 11.46 18.39 13.08 12.06
Gross Profit -42.71 12.63 9.94 8.68
Operating Income -91.88 -112.14 -114.61 -101.39
Net Income -218.76 -40.81 -144.42 -119.8

SRNE Balance Sheet

Quick Ratio MRQ 1.09
Current Ratio MRQ 1.35
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 154.98%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Total Assets 632.13 855.64 694.82 752.79
Total Liabilities 496.37 629.09 616.07 621.29
Total Equity 135.76 226.54 78.75 131.5

SRNE Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -55.73%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Period Length: 0 Months 3 Months 12 Months 0 Months
Cash From Operating Activities -80.99 -83.36 -281.82 -209.68
Cash From Investing Activities -1.73 -13.66 79.85 82.05
Cash From Financing Activities 41.77 173.37 181.33 110.47
Net Change in Cash -41.56 75.24 -19.8 -16.73
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SRNE Comments

Write your thoughts about Sorrento Therape
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
DPP TCR
DPP TCR Sep 21, 2022 12:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1.70 again, ouch!
DPP TCR
DPP TCR Aug 30, 2022 12:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
jeez what a beating, is it never gonna end?
DPP TCR
DPP TCR Jun 11, 2022 12:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
so took the 'a' out of the *****
DPP TCR
DPP TCR Jun 11, 2022 12:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
they bleeped out the word 'rectl' cancer
DPP TCR
DPP TCR Jun 11, 2022 12:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dostarlimab from the pharmaceutical company GlaxoSmithKline acheives 100% success in treating patients with *******cancer - 14 patients in one study show no form of *******cancer after the treatment. Wonder what our guys at SRNE are doing, other companies are getting their magic bullets. Good lord if any of you guys own GlaxoSmithKline, good on ya, thats going to get you set for the start of a good life. Hope SRNE jumps on the bandwagon soon enough.
Robert Poot
Robert Poot May 25, 2022 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I just bought another 1000 shares. research says its a bargain, value = 3.4 a share
DPP TCR
DPP TCR May 25, 2022 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Respect buddy, average it out.I would love to have my cost price at $1.60, but would need to buy 200,000 shares! haha
Matt Skinner
Matt Skinner May 02, 2022 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This compny will reverse split before you see 3 agian just sell.
mark slaughter
mark slaughter May 02, 2022 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You must be shorting the stock
DPP TCR
DPP TCR Apr 29, 2022 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gents I've gotta level with you, as Crim Jamer mentioned on 18th April 2022, the possibility of SRNE going below $1 seems very much likely...If I had the cash I would definitely buy more and average but the fact is for this to come back to a solid $10 and above range is going to be a waiting period of at least 5 years..hoping the time period is less but things look really f88ked up, pretty much operators manipulating the stock to have us sell off and they can reap this really cheap and then enjoy selling it out at anywhere between $12 - $18, while we look on as twits. Those who can average they should, those who can't lets wait it out.
mark slaughter
mark slaughter Apr 29, 2022 11:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What are you??… a human crystal ball!?!?… 5 years???🤔… you think its gonna be 5 years before anything is approved??
Sudipto Adhikari
Sudipto Adhikari Apr 21, 2022 7:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This needs to have M&A !!!!!!!!!!!
Edwin Henriquez
Edwin Henriquez Apr 18, 2022 2:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
really something else this company and if you notice they haven't promoted any news is like they want this stock to zinc to a dollar level
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email